4//SEC Filing
Klee Justin B. 4
Accession 0000950170-24-122640
CIK 0001658551other
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 7:24 PM ET
Size
6.6 KB
Accession
0000950170-24-122640
Insider Transaction Report
Form 4
Klee Justin B.
DirectorCo-Chief Executive Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-11-04−63,690→ 36,310 totalExercise: $1.57Exp: 2025-02-26→ Common Stock (63,690 underlying) - Exercise/Conversion
Common Stock
2024-11-04$1.57/sh+63,690$99,993→ 3,184,259 total
Footnotes (1)
- [F1]This option is fully vested and exercisable.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001898314
Filing Metadata
- Form type
- 4
- Filed
- Nov 5, 7:00 PM ET
- Accepted
- Nov 6, 7:24 PM ET
- Size
- 6.6 KB